Setting a research agenda for medical overuse

Citation

Published Version
doi:10.1136/bmj.h4534

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:22856952

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Setting a research agenda for medical overuse

Although overuse in medicine is gaining increased attention, many questions remain unanswered. Dan Morgan and colleagues propose an agenda for coordinated research to improve our understanding of the problem.

Daniel J Morgan associate professor," Shannon Brownlee writer", Aaron L Leppin postdoctoral research fellow," Nancy Kressin professor", Sanket S Dhruva research fellow," Les Levin professor" Bruce E Landon professor", Mark A Zezza vice president", Harald Schmidt assistant professor", Vikas Saini president", Adam G Elshaug Adam G Elshaug, Associate Professor and HCFRF Principal Research Fellow and, Senior Fellow"

Overuse of medical services is common. In the United States, overuse represents as much as 30% of provided services and has been associated with worse outcomes and death. The problem has existed for decades, but despite heightened recognition in recent years, many gaps remain in our basic understanding of its scope, drivers, and potential for harming patients physically, mentally, and financially. Recent efforts on overuse include a joint statement by the American Board of Internal Medicine and Academy Health calling for improved definitions of medical overuse, and the Robert Wood Johnson Foundation recommended changes in state policy to reduce overuse.

Although the Agency for Healthcare Research and Quality (AHRQ) sponsored a report on medical overuse in 2009, this report did not delineate a framework for research. Research into overuse remains poorly coordinated and terms such as overuse, overdiagnosis, and low value care are all used to describe various interpretations of the concept. Without a common language or conceptual framework to connect research efforts and objectives, understanding of overuse will remain fragmented and limit our ability to make healthcare safer, less expensive, and more patient centered. Calls have been made for a research agenda. This article provides a conceptual framework organizing the current research on overuse and formulating a research agenda. It reflects the consensus opinions of a working group of clinicians and researchers convened by the Lown Institute in December 2013.

What do we know about overuse?

Definitions

The Institute of Medicine and others have defined overuse as “care in the absence of a clear medical basis for use or when the benefit of therapy does not outweigh risks.” Closely related terms for overuse, often used as synonyms include overtreatment, overmedicalization, and low value care. Other related concepts include overdiagnosis—the diagnosis of conditions that will never cause symptoms or harm during a patient’s lifetime—and overtreatment—treatment that “according to sound science and the patient’s own preferences, cannot possibly help.” Figure 1 shows the relation between overdiagnosis, overtreatment, and overuse.

Frequency of overuse

Estimates of the scope of overuse vary from 10% to 30% of all care depending on the definition and method used (surveys of physicians or patients or claims data). Claims data have been used in “top down” approaches to identify geographic regions that use more surgery, hospitalization, and medical care. Such excess care has been associated with higher risk adjusted mortality.

Recently, administrative data have been used to measure use of “do not do” practices. Most articles on overuse have examined outcomes that follow screening or diagnostic tests or discrete treatments. These investigations have identified potential overuse and established an evidence based...
Develop agency(ies) to monitor overuse of diagnoses and treatments—Frequency of overuse has generally been identified retrospectively in only a few specific clinical areas. Given the importance of overuse, development of national agencies (or initially, branches within an agency) with authority similar to the US or European Centers for Disease Control and Prevention is a priority to monitor for “outbreaks” in use of diagnostic and treatment methods and variation in routine care. Surveillance of diagnostic billing codes and use of tests and therapies could be developed with appropriate methods for defining rates that account for changes in costs, reimbursements, and new tests. Such agencies could provide real time monitoring as well as annual descriptions of changes in rates of overuse along with potential contributing factors.

Factors promoting overuse

Many factors contribute to overuse (table⇓). Some relate primarily to patients, others to providers. Some factors relate more to intrinsic (patient or provider beliefs) and others to extrinsic pressure (related to healthcare systems). The relative importance of different causes of overuse is unknown.

Effect of overuse

The full effect of overuse on patients and health systems remains unknown. Clear patient harms have been identified from practices such as screening for breast, prostate, and thyroid cancer. Similarly, magnetic resonance imaging for uncomplicated back pain can lead to surgery that poses net harm to patients. The risk of harm from overuse varies depending on the disease, its treatment, and the rate of overuse of the therapy. Unnecessary treatment burden (the activities required of patients to access and use care and navigate complex healthcare systems) is an additional negative consequence of overuse.

Strategies to mitigate overuse

Various approaches focusing on patients, providers, or system changes have been used in an attempt to limit overuse and have had varying success. Efforts to promote patient engagement, such as shared decision making, may reduce overuse. At the provider level, some clinical practice guidelines have become less aggressive in their treatment recommendations. Provider groups have also developed lists of clinical interventions that offer little net benefit (low value lists). Expanded understanding of the number needed to treat (NNT) has been proposed as a way to discuss overtreatment. At the system level, tools to limit overuse may include constraining resources through regulatory mechanisms such as Certificates of Need and insurance mandated preapprovals; regulating access to testing and treatment; global payment contracts (such as accountable care organizations) or strategies that increase patient cost sharing (such as high deductible health plans); changing reimbursement and care models to prioritize primary care; and robust assessment for new and existing medical technology. The effect of such changes on overuse, however, is largely understudied.

Research agenda for medical overuse

Although definitions related to overuse and understanding of its frequency and causes have advanced, we still need research to answer fundamental questions related to overuse to improve patient care (box). Below we discuss these in more detail.

Measure the frequency of overuse

Develop agency(ies) to monitor overuse of diagnoses and treatments—Frequency of overuse has generally been identified retrospectively in only a few specific clinical areas. Given the importance of overuse, development of national agencies (or
Research agenda for medical overuse

Measure frequency of overuse
- Develop an agency to monitor overuse of diagnoses and treatments
- Define the scope of overdiagnosis and overtreatment in medicine
- Capture clinical information in administrative data that would allow for better assessment of overuse

Identify factors promoting overuse
- Identify the most important drivers of overuse
- Understand and communicate limitations in diagnostic testing

Explore how clinical uncertainty and cognitive biases may lead to overuse
- Measure the impact of overuse
- Study the full impact of overuse on patients in terms of physical and psychological harm
- Study the effect of overuse on treatment burden

Strategies to mitigate overuse
- Understand the impact of Choosing Wisely and other initiatives on clinical practice and patient outcomes
- Understand patient and clinician views on the acceptability and legitimacy of different methods to encourage appropriate care
- Investigate how patients understand overuse and the best methods for communicating harms of overuse to patients
- Examine the effect of shared decision making and other patient directed interventions on overuse

Modifications to research infrastructure
- Develop common terminology (MeSH terms)
- Improve institutional review boards’ understanding of overuse
- Address overuse in guidelines

*Research priorities

Study the effect of overuse on treatment burden—Further understanding of how patients experience treatment burden is also needed, along with quantification of its effect and how to lessen treatment burden in clinical practice. A more complete description of the negative consequences of overuse at a patient level could lead to metrics for interventional trials or performance improvement. Methods to examine harms and treatment burden will likely include cross sectional, retrospective, prospective cohort, and qualitative studies.

Strategies to mitigate overuse
Understand the effect of low value lists on clinical practice and patient outcomes—Although Choosing Wisely, the most publicly visible effort to limit overuse,18–20 has publicized the problem, its impact on patient care is not well described. This should be studied, probably in cross sectional and cohort studies with patient level or administrative data.

Understand patient views on the acceptability and legitimacy of different methods to encourage appropriate care—The concept of overuse implies setting limits on care, which may evoke concerns about rationing. Various policies are available to discourage overuse, such as ceasing to pay for low value interventions, and we need to assess the short and long term effectiveness and acceptability of both established and novel approaches. Surveys and qualitative methods will likely be most useful.

Investigate how patients understand overuse and the best methods for communicating its harms—If and when patients understand overuse is not well understood. Likewise, we do not know how patient expectations lead to overuse and which health beliefs create expectations for overuse. Studies are needed to determine the best methods to communicate with and educate patients on overuse in a way that will affect their decisions. Methods will likely include qualitative studies and quasiexperimental work.

Examine the effect of shared decision making and other patient focused interventions on overuse—Though shared decision making is often invoked as means of reducing overuse, its effect is generally not known and merits study in qualitative and quasiexperimental research or randomized trials.

Modifications to research infrastructure
Create common terminology—Appropriate MeSH terms and keywords for searches in PubMed and other engines are needed to identify overuse literature with greater specificity and to improve communication of results across disciplines.

Improve institutional review boards’ understanding of overuse research—Boards need to be made aware of the lack of evidence behind many current medical practices and of the growing body of evidence highlighting deficits in the safety and effectiveness of many others. Without evidence for standard practice, the balance of benefits to risks is such that placebo or no treatment may be acceptable comparisons to standard of care.

Address overuse in guidelines—Guidelines generally recommend when to treat but not when to avoid treatment. Often, guideline recommendations are extrapolated to diseases or patients in which the intervention was never studied (such as patients with complex multimorbidity).38,39 We recommend guidelines include recommendations of when not to test or treat, limitations to existing evidence, and a section on “possibility for overuse.” Also of interest is whether “do not do” recommendations might reduce the practice of “defensive medicine.”

Funding
These research agenda items will require creative approaches and determined individuals to better understand, describe, and ultimately improve medical care. Such work will require support. Public agencies such as the US National Institutes of Health, Agency for Healthcare Research and Quality, Patient Centered Outcomes Research Institute, Department of Veterans Affairs, CDC, United Kingdom research councils, European Commission, and Australia’s National Health and Medical Research Council should devote a portion of funding towards the study of overuse. Foundations such as Robert Wood Johnson...
Overuse of medical care is an increasingly recognized problem that affects costs and patient safety and satisfaction. Standardizing terms such as overdiagnosis and overtreatment, campaigns such as Choosing Wisely, and journal sections focused on overuse, including those by The BMJ (www.bmj.com/too-much-medicine), JAMA, and Annals of Internal Medicine, are helping build awareness. The priorities for future research include developing public agencies to monitor overuse; defining the scope of overuse as well as physical and psychological harms; evaluating the effect of Choosing Wisely and other efforts to curb overuse; improving understanding of overuse by review boards and guidelines panels; and adopting standard terminology for library search engines. With concerted research efforts, the coming years could greatly improve our knowledge of overuse to maximize the benefits of medical care.

We thank Lisa Pineles and Lindsay Croft for editorial assistance. We thank the Robert Wood Johnson Foundation who contributed funding support for the 2013 Lown Institute conference where this workshop, chaired by AGE and attended by all authors, took place. The views presented here are those of the authors and do not reflect those of the funders, including their officers and staff.

Contributors and sources: This article derives from a working group of clinicians and researchers in Boston convened by the Lown Institute in December 2013 to develop a research agenda for medical overuse. Competing interests: We have read and understood BMJ policy on declaration of interests and declare the following interests: DJM received research support from the VA Health Services Research (CRE 12-307), Agency for Healthcare Research and Quality (AHRQ) (K08-HS18111). He has consulted for Welch Allyn for research development and provided self developed lecture in a 3M sponsored series. NRR received support from a VA Health Services Research and Development Senior Research Career Scientist award (K02-00220). ACE received salary support as the HCF Research Foundation principal research fellow and holds an Australian NHMRC Sidney Sax fellowship (ID 627061). He receives consulting/sitting fees from Cancer Australia, the Capital Markets Cooperative Research Centre-Health Quality Program, NPS MedicineWise (facilitator of Choosing Wisely Australia), and the Australian Commission on Safety and Quality in Health Care and is appointed to the Medicare Benefits Schedule Reviews Taskforce. Provenance and peer review: Not commissioned; externally peer reviewed.

1. Deyo RA, Patrick DL. Hope or hype: the obsession with medical advances and the high cost of false promises. AMACOM, American Management Association, 2005.
Key messages

Research into the effects of overuse in medicine is uncoordinated
More research is needed to define the extent of overuse and its harms
Adoption of standard terminology is essential to better understanding
Public agencies are needed to monitor overuse
Evaluation of current efforts to curb overuse is also a priority

61 Lencer J. Majority of panelists on controversial new cholesterol guideline have current or recent ties to drug manufacturers. BMJ 2013;347:f6899.

Cite this as: BMJ 2015;351:h4534
© BMJ Publishing Group Ltd 2015

Accepted: 30 July 2015

For personal use only: See rights and reprints http://www.bmj.com/permissions
Subscribe: http://www.bmj.com/subscribe
### Table 1 | Provider and patient factors identified as causing overuse of medical care

<table>
<thead>
<tr>
<th>Provider driven</th>
<th>Extrinsic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belief more care is better&lt;sup&gt;45,46&lt;/sup&gt;</td>
<td>Financial—provider&lt;sup&gt;45&lt;/sup&gt; and hospital&lt;sup&gt;45,46&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lack of knowledge of harm from overuse&lt;sup&gt;15,16&lt;/sup&gt;</td>
<td>Resource supply&lt;sup&gt;13&lt;/sup&gt;</td>
</tr>
<tr>
<td>Discomfort with uncertainty&lt;sup&gt;40,41,42,43&lt;/sup&gt;</td>
<td>Defensive medicine&lt;sup&gt;26&lt;/sup&gt;</td>
</tr>
<tr>
<td>Poor knowledge of patient preference&lt;sup&gt;23&lt;/sup&gt;</td>
<td>Variation in medical and surgical practice&lt;sup&gt;44,50,54&lt;/sup&gt;</td>
</tr>
<tr>
<td>Regret for errors of omission greater than commission&lt;sup&gt;39,40&lt;/sup&gt;</td>
<td>Process measures&lt;sup&gt;27&lt;/sup&gt;</td>
</tr>
<tr>
<td>Belief action better than inaction&lt;sup&gt;39,40&lt;/sup&gt;</td>
<td>Inadequate time&lt;sup&gt;37,38&lt;/sup&gt;</td>
</tr>
<tr>
<td>Use of therapeutics &quot;off label&quot;&lt;sup&gt;75&lt;/sup&gt;</td>
<td>Positive publication bias&lt;sup&gt;84,85,86&lt;/sup&gt;</td>
</tr>
<tr>
<td>Over-reliance on pathophysiological and anatomical reasoning</td>
<td>Guidelines promoting overuse&lt;sup&gt;87,88&lt;/sup&gt;</td>
</tr>
<tr>
<td>Desire for reassurance&lt;sup&gt;94&lt;/sup&gt;</td>
<td>Medical culture&lt;sup&gt;89&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lack of training in shared decision making&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Advocacy groups&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lack of knowledge of harm from overuse&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Medicalization of non-disease (eg, baldness)&lt;sup&gt;48,52&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient driven</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Belief more care is better&lt;sup&gt;45,46&lt;/sup&gt;</td>
<td>Financial—third party payment shielding from costs&lt;sup&gt;16&lt;/sup&gt;</td>
</tr>
<tr>
<td>Lack of knowledge of harm from overuse&lt;sup&gt;1&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Discomfort with uncertainty&lt;sup&gt;47,48&lt;/sup&gt;</td>
<td>Culture of avoiding mortality&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Media misrepresentation of research&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Advocacy groups&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Medicalization of non-disease (eg, baldness)&lt;sup&gt;18,56&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
Figure

![Diagram showing the relation between overdiagnosis, overtreatment, and overuse.](image-url)

**Fig 1** Relation between overdiagnosis, overtreatment, and overuse